J&J Completes Acquisition of Actelion
The company said it expects to transaction to close on June 16, 2017.
On June 16, 2017, Johnson & Johnson (J&J) announced that has completed the acquisition of Actelion. Earlier in June, the company said that it received approval from the European Commission, and that all regulatory approvals required to complete the transaction have been received. J&J said that it expected the transcation to close on June 16, 2017.
The $30-billion acquisition of Actelion by J&J was originally announced on Jan. 26, 2017. As previously announced, as part of the transaction, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. The shares of Idorsia Ltd are expected to be distributed to Actelion's shareholders as a dividend in kind and listed on the SIX Swiss Exchange on the day of the settlement of the public tender offer. A J&J subsidiary will initially hold 9.9% of the shares of Idorsia Ltd and has rights to potentially increase up to 32% through a convertible note.
Source: Johnson & Johnson
This article was updated on June 19, 2017.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
